SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of July 2021
Commission file number: 001-39838
Gracell Biotechnologies Inc.
Building 12, Block B, Phase II
Biobay Industrial Park
218 Sangtian St.
Suzhou Industrial Park, 215123
Peoples Republic of China
(Address of Principal Executive Offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
|99.1||Voting Results of 2021 Annual General Meeting|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|Gracell Biotechnologies Inc.|
|Name:||William Wei Cao|
|Title:||Chairman of the Board of Directors and|
Chief Executive Officer
Date: July 12, 2021
Voting Results of 2021 Annual General Meeting
At Gracell Biotechnologies Inc.s (the Company) annual general meeting of shareholders held on July 9, 2021 (the AGM), the Companys shareholders:
Elected Mr. Christophe Lee to serve as Class I director of the Company.
A total of 263,917,715 ordinary shares, including those underlying ADSs, representing approximately 78.53% of the ordinary shares issued and outstanding as of June 2, 2021, the record date, were present in person or by proxy at the AGM. The results of the votes are as follows:
Election of Director
Mr. Christophe Lee (Class I)
Represents less than 0.001% of votes.